Upstream Bio (UPB) Receivables (2023 - 2026)

Upstream Bio's Receivables history runs 4 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Receivables rose 50.0% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (up 50.0% YoY), while the FY2025 annual figure was $2.3 million, up 96.69% from the prior year.
• Receivables for Q1 2026 stood at $2.6 million, up from $2.3 million in the prior quarter.
• The five-year high for Receivables was $2.6 million in Q2 2025, with the low at $236000.0 in Q4 2023.
• The 4-year median for Receivables is $1.7 million (2025), against an average of $1.6 million.
• The sharpest annual moves came in 2024 and 2026: Receivables surged 400.0% in 2024, then soared 50.0% in 2026.
• Upstream Bio's Receivables stood at $236000.0 in 2023, then soared by 400.0% to $1.2 million in 2024, then surged by 96.69% to $2.3 million in 2025, then gained by 12.32% to $2.6 million in 2026.
• Business Quant data shows UPB's Receivables at $2.6 million in Q1 2026, $2.3 million in Q4 2025, and $2.3 million in Q3 2025.